Home
/
Kalaris Therapeutics, Inc.
/
Financials
/
Quarterly
Kalaris Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Kalaris Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2020
Sep 30, 2019
$165.0K
Nov 10, 2020
Q2
2020
Jun 30, 2019
$165.0K
Sep 2, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($11.89M)
Nov 12, 2025
Q3
2025
Jun 30, 2025
($11.35M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($11.35M)
Aug 13, 2025
Q1
2025
Mar 31, 2025
($10.20M)
May 14, 2025
Q3
2025
Mar 31, 2025
($10.20M)
Nov 12, 2025
Q2
2025
Mar 31, 2025
($10.20M)
Aug 13, 2025
Q3
2025
Sep 30, 2024
($38.08M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($5.65M)
Aug 13, 2025
Q3
2025
Jun 30, 2024
($5.65M)
Nov 12, 2025
Q1
2025
Mar 31, 2024
($3.41M)
May 14, 2025
Q3
2025
Mar 31, 2024
($3.41M)
Nov 12, 2025
Q2
2025
Mar 31, 2024
($3.41M)
Aug 13, 2025
Q3
2024
Sep 30, 2023
($44.27M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($45.27M)
Aug 9, 2024
Q3
2024
Jun 30, 2023
($45.27M)
Nov 12, 2024
Q3
2024
Mar 31, 2023
($41.18M)
Nov 12, 2024
Q2
2024
Mar 31, 2023
($41.18M)
Aug 9, 2024
Q1
2024
Mar 31, 2023
($41.18M)
May 13, 2024
Q3
2023
Sep 30, 2022
($42.07M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($44.64M)
Aug 3, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($12.74M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($12.26M)
Aug 13, 2025
Q1
2025
Mar 31, 2025
($10.35M)
May 14, 2025
Q3
2025
Sep 30, 2024
($37.85M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($4.19M)
Aug 13, 2025
Q1
2025
Mar 31, 2024
($2.56M)
May 14, 2025
Q3
2024
Sep 30, 2023
($46.96M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($47.30M)
Aug 9, 2024
Q1
2024
Mar 31, 2023
($43.23M)
May 13, 2024
Q3
2023
Sep 30, 2022
($42.95M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($44.62M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($43.19M)
May 4, 2023
Q3
2022
Sep 30, 2021
($45.50M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($37.66M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($30.86M)
May 5, 2022
Q3
2021
Sep 30, 2020
($23.90M)
Nov 5, 2021
Q2
2021
Jun 30, 2020
($12.15M)
Aug 6, 2021
Q1
2021
Mar 31, 2020
($9.84M)
May 6, 2021
Q3
2020
Sep 30, 2019
($8.48M)
Nov 10, 2020
Q2
2020
Jun 30, 2019
($5.95M)
Sep 2, 2020